Comparative Pharmacology
Head-to-head clinical analysis: BOSUTINIB MONOHYDRATE versus INLYTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BOSUTINIB MONOHYDRATE versus INLYTA.
BOSUTINIB MONOHYDRATE vs INLYTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bosutinib is a dual Src/Abl tyrosine kinase inhibitor. It inhibits the BCR-ABL kinase, which is constitutively active in chronic myeloid leukemia (CML), and also inhibits Src family kinases. It has minimal inhibitory activity against c-KIT and PDGFR.
Axitinib is a tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3), which are involved in pathologic angiogenesis, tumor growth, and metastatic progression of cancer.
400 mg orally once daily with food.
5 mg orally twice daily, approximately 12 hours apart, with or without food.
None Documented
None Documented
22.5 hours; supports once-daily dosing, with steady-state achieved by day 8.
Terminal elimination half-life is approximately 13–17 hours in patients, supporting twice-daily dosing.
Primarily fecal (91%, as unchanged drug and metabolites) with renal excretion accounting for <3%.
Primarily hepatic metabolism via CYP3A4 and subsequent biliary-fecal elimination (approximately 61% of dose recovered in feces, 23% in urine as metabolites; <10% excreted unchanged in urine or feces).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor